Zhejiang Taimei Medical Technology Co., Ltd. Is Now Listed on HKEX

October 14, 2024 01:18 PM AEDT | By Cision

Zhejiang Taimei Medical Technology Co., Ltd. Is Now Listed on HKEX — Image source: Kalkine Media

Recent News

ASX Approaches Record Close as Mining Stocks Rally

QNB Unifies Its Brand to Enhance Global Presence

ASX Nears Record Close as Mining Stocks Lead Late Rally

SolaX Power Wins SMM Global Tier 1 Award for Battery Energy Storage Sy...

HONG KONG, Oct. 14, 2024 /PRNewswire/ -- Zhejiang Taimei Medical Technology Co., Ltd. (the "Company"; Stock code: 2576.HK) has announced that the shares have started to be traded on the Main Board of the Stock Exchange of Hong Kong Limited under the stock code "2576" since today.

The Company said, "in the future, we will continue to upgrade and expand our products and services; expand customer base and efficiently respond to customer needs; strengthen customer relationships through cross-selling and upselling; reinforce R&D for future growth; expand internationally and foster global collaboration; pursue business growth through investments, acquisitions and partnerships."

Looking forward, taking the listing as an opportunity, the Company will leverage on the global capital to further promote its business development, strive for outstanding performance, and give back to the shareholders, the society and the public.

Zhejiang Taimei Medical Technology Co., Ltd. designs and provides industry-specific software and digital services to a variety of stakeholders in the pharmaceutical and medical device industry. The Company is the largest digital solution provider for pharmaceutical and medical device R&D and commercialization in China in terms of revenue in 2023, taking up a market share of 5.9%.

According to CIC. As of March 31, 2024, The Company offered more than 40 software products and digital services that cater to diverse organizational needs and roles within the pharmaceutical and medical device industry, in various use cases such as trial design and management, patient recruitment and follow-up, data collection and analysis, remote monitoring, as well as sales relationship management. Through seamless integration of digital services with software on platforms, the Company deliver efficient and high-quality one-stop solutions that streamline processes throughout the pharmaceutical and medical device R&D and commercialization journey, enhancing efficiency and improving quality.

According to CIC. As of March 31, 2024, the Company had served over 1,400 pharmaceutical companies and contract research organizations, including 21 out of the top 25 global pharmaceutical companies and 90 of the top 100 Chinese pharmaceutical innovators, making it the most widely adopted digital solution provider for pharmaceutical and medical device R&D and commercialization in China in terms of number of customers.

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (“Kalkine Media, we or us”), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary.
The content published on Kalkine Media also includes feeds sourced from third-party providers. Kalkine does not assert any ownership rights over the content provided by these third-party sources. The inclusion of such feeds on the Website is for informational purposes only. Kalkine does not guarantee the accuracy, completeness, or reliability of the content obtained from third-party feeds. Furthermore, Kalkine Media shall not be held liable for any errors, omissions, or inaccuracies in the content obtained from third-party feeds, nor for any damages or losses arising from the use of such content.
Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyrighted to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have made reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.

This disclaimer is subject to change without notice. Users are advised to review this disclaimer periodically for any updates or modifications.